Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (9)	5/12/2000 2:01:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 1336

Went to the Tgen annual meeting earlier this morning, nothing new that I detected--but a nice meeting nonetheless. We were told to watch out for news flow over the year ahead etc etc. HS Parker again reiterated that the company has strong intellectual property for delivering the CFTR gene via AAV. Asked a question of Barrie Carter afterward, serotypes and such--that was pretty cool, you will see AAV5 in a few abstracts out there, but I certainly don't have any reason to expect that Tgen will not have some measure of success with AAV2 giving expression for CF, sure hope so--the sure picked a tough problem. I guess I have to do a little follow-up cell biology 101 however, receptors and gene therapy vectors etc, as much of what Mr. Carter said sailed comfortably over my head, no surpise there;-) The best part of course was that about twenty of the employees were in the back of the room, so they stood up and got a round of applause, very nice.